Table 1.
List of control, p‐preAD, and AD cases used for analysis of CAA and plaques
| No | Agea | Genderb | Diagnosisc | Diabetes mellitusd | Hyper‐tensiond | Alcohol abused | CDR scoree | Aβ‐MTL phasef | Braak‐NFT stageg | CERAD scoreh | NIA‐AA AD degreei | APOE genotypej | B‐Aβ plaque stagek | B‐CAA stage |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 60 | M | Control | ‐ | + | ‐ | 0 | 0 | 0 | 0 | not AD | “2/3” | 0 | 0 |
| 2 | 69 | F | Control | ‐ | + | ‐ | 0 | 0 | 1 | 0 | not AD | “3/3” | 0 | 0 |
| 3 | 66 | M | Control | ‐ | ‐ | ‐ | 0 | 0 | 1 | 0 | not AD | “3/3” | 0 | 0 |
| 4 | 71 | F | Control | ‐ | + | ‐ | 0 | 0 | 1 | 0 | not AD | “2/3” | 0 | 0 |
| 5 | 58 | F | Control | + | ‐ | ‐ | 0 | 0 | 0 | 0 | not AD | “3/3” | 0 | 0 |
| 6 | 46 | M | Control | ‐ | ‐ | ‐ | 0 | 0 | 1 | 0 | not AD | “3/3” | 0 | 0 |
| 7 | 45 | M | Control | ‐ | ‐ | ‐ | 0 | 0 | 0 | 0 | not AD | “3/4” | 0 | 0 |
| 8 | 35 | M | Control | ‐ | ‐ | ‐ | 0 | 0 | 0 | 0 | not AD | “3/3” | 0 | 0 |
| 9 | 59 | M | Control | ‐ | ‐ | + | ‐ | 0 | 1 | 0 | not AD | “3/4” | 0 | 0 |
| 10 | 57 | M | Control | ‐ | ‐ | ‐ | 0 | 0 | 1 | 0 | not AD | “3/4” | 0 | 0 |
| 11 | 74 | M | Control | ‐ | ‐ | ‐ | 0 | 0 | 1 | 0 | not AD | “3/4” | 0 | 0 |
| 12 | 66 | M | Control | ‐ | ‐ | + | 0 | 0 | 1 | 0 | not AD | “3/3” | 0 | 0 |
| 13 | 61 | M | Control | ‐ | + | ‐ | 0 | 0 | 0 | 0 | not AD | “3/3” | 0 | 0 |
| 14 | 66 | M | Control | + | ‐ | ‐ | 0 | 0 | 1 | 0 | not AD | “2/3” | 0 | 0 |
| 15 | 60 | M | Control | ‐ | ‐ | ‐ | 0 | 0 | 1 | 0 | not AD | “3/3” | 0 | 0 |
| 16 | 69 | F | Control | ‐ | + | ‐ | 0 | 0 | 0 | 0 | not AD | “2/3” | 0 | 0 |
| 17 | 66 | F | Control | ‐ | + | + | 0 | 0 | 0 | 0 | not AD | “3/3” | 0 | 0 |
| 18 | 62 | M | Control | ‐ | ‐ | + | 0 | 0 | 0 | 0 | not AD | “3/3” | 0 | 0 |
| 19 | 72 | F | Control | + | + | ‐ | 0 | 0 | 1 | 0 | not AD | “3/3” | 0 | 0 |
| 20 | 62 | M | Control | ‐ | ‐ | ‐ | 0 | 0 | 0 | 0 | not AD | “3/3” | 0 | 0 |
| 21 | 72 | F | p‐preAD | + | + | ‐ | 0 | 1 | 2 | 0 | low | “3/3” | 2 | 0 |
| 22 | 71 | M | p‐preAD | + | ‐ | ‐ | 0 | 3 | 2 | 1 | low | “2/4” | 3 | 3 |
| 23 | 68 | F | p‐preAD | ‐ | ‐ | ‐ | 0 | 2 | 2 | 0 | low | “2/3” | 3 | 3 |
| 24 | 73 | F | p‐preAD | ‐ | + | ‐ | 0 | 1 | 2 | 0 | low | “3/3” | 2 | 0 |
| 25 | 77 | F | p‐preAD | ‐ | ‐ | ‐ | 0 | 3 | 2 | 0 | low | “3/4” | 3 | 0 |
| 26 | 78 | F | p‐preAD | ‐ | ‐ | ‐ | 0 | 3 | 2 | 0 | low | “3/4” | 3 | 3 |
| 27 | 71 | F | p‐preAD | ‐ | + | ‐ | 0 | 3 | 2 | 1 | low | “3/3” | 2 | 3 |
| 28 | 77 | F | p‐preAD, VD | + | + | ‐ | 3 | 2 | 3 | 1 | low | “3/3” | 2 | 3 |
| 29 | 73 | F | p‐preAD | ‐ | ‐ | ‐ | 0 | 1 | 2 | 0 | low | “2/3” | 2 | 0 |
| 30 | 74 | M | p‐preAD | + | + | ‐ | 0 | 2 | 2 | 0 | low | “3/3” | 2 | 0 |
| 31 | 64 | M | p‐preAD, brain infarction | ‐ | + | ‐ | ‐ | 2 | 1 | 0 | low | “3/3” | 2 | 0 |
| 32 | 74 | M | p‐preAD | + | + | ‐ | 0 | 4 | 3 | 1 | intermediate | “3/4” | 3 | 1 |
| 33 | 53 | M | p‐preAD | ‐ | ‐ | ‐ | 0 | 1 | 1 | 0 | low | “3/3” | 2 | 0 |
| 34 | 78 | F | p‐preAD, VD, CBD | ‐ | + | ‐ | 3 | 1 | 1 | 0 | low | “3/3” | 2 | 0 |
| 35 | 68 | F | p‐preAD | ‐ | + | ‐ | 0 | 2 | 1 | 0 | low | “3/3” | 2 | 0 |
| 36 | 67 | F | p‐preAD | + | ‐ | ‐ | 0 | 2 | 2 | 0 | low | “3/3” | 2 | 0 |
| 37 | 82 | F | p‐preAD, microinfarcts | ‐ | + | ‐ | ‐ | 2 | 1 | 1 | low | “3/3” | 2 | 3 |
| 38 | 87 | M | p‐preAD | ‐ | + | ‐ | 0 | 3 | 3 | 1 | intermediate | “3/4” | 3 | 3 |
| 39 | 84 | F | p‐preAD | ‐ | + | ‐ | 0 | 3 | 2 | 0 | low | “2/3” | 3 | 0 |
| 40 | 84 | F | p‐preAD, brain infarction | ‐ | ‐ | ‐ | 0 | 3 | 3 | 0 | intermediate | “3/3” | 3 | 3 |
| 41 | 88 | M | p‐preAD, AGD | ‐ | + | ‐ | 2 | 3 | 2 | 1 | low | “2/3” | 3 | 2 |
| 42 | 83 | F | p‐preAD | + | ‐ | ‐ | 0 | 3 | 3 | 1 | intermediate | “2/3” | 3 | 1 |
| 43 | 72 | M | p‐preAD | + | ‐ | ‐ | 0 | 2 | 3 | 0 | low | “3/3” | 2 | 0 |
| 44 | 64 | M | p‐preAD | ‐ | ‐ | ‐ | 0 | 2 | 1 | 0 | low | “3/3” | 2 | 0 |
| 45 | 63 | F | p‐preAD, brain infarction | ‐ | ‐ | ‐ | 0 | 4 | 3 | 1 | intermediate | “3/3” | 2 | 0 |
| 46 | 85 | F | p‐preAD | + | ‐ | ‐ | 0 | 4 | 3 | 1 | intermediate | “3/3” | 2 | 0 |
| 47 | 83 | M | p‐preAD, brain infarction | + | + | ‐ | 0 | 2 | 3 | 0 | low | “3/3” | 1 | 0 |
| 48 | 79 | F | AD | ‐ | ‐ | ‐ | ‐ | 3 | 4 | 2 | intermediate | “3/3” | 3 | 3 |
| 49 | 64 | F | AD | ‐ | + | ‐ | ‐ | 4 | 6 | 3 | high | “3/4” | 3 | 2 |
| 50 | 62 | F | AD | ‐ | ‐ | ‐ | 3 | 4 | 6 | 3 | high | “3/4” | 3 | 3 |
| 51 | 84 | M | AD | ‐ | ‐ | ‐ | 3 | 4 | 6 | 3 | high | “3/4” | 3 | 2 |
| 52 | 72 | F | AD | ‐ | ‐ | ‐ | 1 | 4 | 4 | 2 | intermediate | “3/3” | 3 | 2 |
| 53 | 83 | M | AD | ‐ | ‐ | ‐ | 1 | 4 | 4 | 2 | intermediate | “3/4” | 3 | 3 |
| 54 | 78 | M | AD | ‐ | ‐ | ‐ | 3 | 4 | 4 | 1 | intermediate | “3/4” | 3 | 2 |
| 55 | 75 | F | AD | ‐ | ‐ | ‐ | 0.5 | 4 | 3 | 1 | intermediate | “4/4” | 3 | 3 |
| 56 | 84 | M | AD, AGD, ALS, VD | ‐ | ‐ | + | 3 | 3 | 4 | 2 | intermediate | “3/3” | 3 | 3 |
| 57 | 68 | F | AD | ‐ | ‐ | ‐ | 1 | 4 | 6 | 3 | high | “3/3” | 3 | 1 |
| 58 | 82 | M | AD | + | + | ‐ | 2 | 3 | 3 | 2 | intermediate | “3/4” | 3 | 3 |
| 59 | 86 | F | AD, AGD | ‐ | ‐ | ‐ | 3 | 4 | 6 | 3 | high | “3/3” | 3 | 3 |
| 60 | 83 | M | AD | ‐ | ‐ | ‐ | 3 | 4 | 4 | 2 | intermediate | “3/3” | 3 | 3 |
| 61 | 78 | F | AD | ‐ | + | ‐ | 3 | 4 | 5 | 3 | high | “3/4” | 3 | 3 |
| 62 | 89 | F | AD | + | ‐ | ‐ | 2 | 4 | 4 | 3 | intermediate | “3/4” | 3 | 3 |
| 63 | 87 | F | AD | ‐ | ‐ | ‐ | 3 | 4 | 4 | 1 | intermediate | “3/3” | 3 | 2 |
| 64 | 78 | M | AD | + | ‐ | ‐ | 1 | 3 | 4 | 1 | intermediate | “3/3” | 3 | 3 |
| 65 | 89 | F | AD | + | ‐ | ‐ | 3 | 4 | 5 | 2 | high | “3/4” | 3 | 2 |
| 66 | 81 | F | AD | + | ‐ | ‐ | 3 | 4 | 5 | 1 | intermediate | “3/3” | 3 | 2 |
| 67 | 83 | M | AD | ‐ | + | ‐ | 3 | 4 | 5 | 3 | high | “4/4” | 3 | 3 |
| 68 | 68 | F | Control, pure CAA | ‐ | + | ‐ | 0 | 0 | 2 | 0 | not AD | “3/3” | 0 | 3 |
| 69 | 64 | F | Control, pure CAA, LBD | ‐ | + | ‐ | 0.5 | 0 | 3 | 0 | not AD | ‐ | 0 | 2 |
| 70 | 63 | F | Control, pure CAA | ‐ | ‐ | ‐ | ‐ | 0 | 2 | 0 | not AD | ‐ | 0 | 2 |
| 71 | 63 | F | Control, pure CAA | + | + | ‐ | 1 | 0 | 1 | 0 | not AD | ‐ | 0 | 2 |
a
age [years].
b
F = female, M = male.
c
AD = Alzheimer's disease, AGD = argyrophilic grain disease, ALS = amyotrophic lateral sclerosis, CAA = cerebral amyloid angiopathy, CBD = corticobasal degeneration, LBD = Lewy body disease, p‐preAD = pathologically‐defined preclinical Alzheimer's disease, VD = vascular dementia.
d
diabetes mellitus/hypertension/alcohol abuse: present (+), absent (‐).
e
clinical dementia rating (CDR) score.64
f
Aβ ‐ medial temporal lobe (MTL) phase.27
h
Consortium to Establish a Registry for Alzheimer's disease (CERAD) score.26
i
National Institute on Aging‐Alzheimer's Association (NIA‐AA) degree of Alzheimer's disease pathology.1, 65
j
APOE = apolipoprotein E.
k
B‐Aβ plaque stage.9